Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease

Last updated: March 23, 2022
Sponsor: TC Erciyes University
Overall Status: Active - Recruiting

Phase

1/2

Condition

Arthritis And Arthritic Pain

Oral Facial Pain

Acute And Chronic Dental Pain

Treatment

N/A

Clinical Study ID

NCT05305833
2021/584
  • Ages 18-65
  • All Genders

Study Summary

It will be evaluate the safety of mesenchymal stem cells and adipose tissue derived stromal vascular fraction (SVF) in temporomandibular joint disease cases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Chronic temporomandibular arthritic disorder
  • History of pain and joint noises for at least 3 months
  • Must have more than VAS 5 TMJ pain
  • must have internal derangement of TMJ
  • Limited mouth opening
  • Magnetic resonance imaging evidence of effusion or degeneration
  • Already treated with conservative methods (occlusal splint,pharmacological and/orphysio-kinesio therapy) without satisfactory benefit.

Exclusion

Exclusion Criteria:

  • Cancer patients
  • Immunosupressed patients
  • Previous TMJ traumas and fractures
  • Previous TMJ surgeries
  • TMJ ankylosis

Study Design

Total Participants: 20
Study Start date:
October 01, 2021
Estimated Completion Date:
December 01, 2023

Study Description

umbilical cord derived mesenchymal stem cells produced under GMP facility in Erciyes University and SVF produced in operation theatre.

Connect with a study center

  • Erciyes University

    Kayseri, 38039
    Turkey

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.